title: Preliminary Experience with Short Course High-Dose Mitoxantrone in Combination with High-Dose Cytarabine in Patients with Acute Leukemia and Blastic Phase of Chronic Myelogenous Leukemia.
abstract: Mitoxantrone is effective therapy for patients with acute leukemia and blastic phase of chronic myelogenous leukemia (CML). In vitro mitoxantrone has a steep dose response curve, which suggests that higher doses given in a shorter duration may result in enhanced leukemic cell kill in vivo. Twenty-four patients with acute leukemia and blastic CML received mitoxantrone 20 mg/m2 I.V. daily × 2 with cytarabine 3 g/m2 I.V. once daily × 5 days. Diagnoses included 8 patients with previously untreated acute non-lymphocytic leukemia (ANLL), 9 patients with relapsed ANLL, 4 patients with refractory acute lymphoblastic leukemia (ALL) and 2 patients with blastic CML. Complete remission was achieved in 8 of 17 patients with ANLL, 1 of 4 patients with ALL and 0 of 2 with blastic CML. Extramedullary toxicity was acceptable and the median time to remission was 26 days (range 20-69). Short course high-dose mitoxantrone with high-dose cytarabine is effective and well-tolerated in patients with acute leukemia.
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: E J
authors.initials: EJ
authors.lastname: Feldman
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: S
authors.initials: S
authors.lastname: Biguzzi
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: T
authors.initials: T
authors.lastname: Ahmed
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: A
authors.initials: A
authors.lastname: Mittelman
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: C A
authors.initials: CA
authors.lastname: Puccio
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: P
authors.initials: P
authors.lastname: Baskind
authors.affiliation: a Department of Medicine, Division of Neoplastic Diseases, New York Medical College, Valhalla, NY.
authors.forename: Z A
authors.initials: ZA
authors.lastname: Arlin
keywords: Mitoxantrone; acute leukemia; high-dose cytarabine